The DNA damage response (DDR) evolved in response to the exposure of the genome to exogenous and endo genous genotoxins. Unless repaired in an errorfree pro cess, DNA damage can result in mutations and altered cellular behaviour. Consequently, cells deploy a diverse repertoire of mechanisms to maintain genetic integrity 1 (TABLE 1) . These mechanisms involve the DNA repair processes themselves, the systems that regulate and organize them, and the systems that integrate DNA damage repair with the cell cycle 2 . Disruption of the DDR is observed in many can cers [3] [4] [5] and it underlies the genomic instability that accompanies tumorigenesis and progression. However, in most cases, the specific underlying defects are poorly characterized 6, 7 . Conversely, there are welldescribed cancers in which disruption of a DDR mechanism is directly causal. For example, Lynch syndrome (also known as hereditary nonpolyposis colorectal can cer (HNPCC)) is associated with lossoffunction mutations in mismatch repair (MMR) genes -most commonly mutS homologue 2 (MSH2) and mutL homologue 1 (MLH1) 8 . Current theories propose that DDR defects in tumour development and progression are positively selected by the need to tolerate oncogene induced replication stress 9,10 and/or by the adaptive advantage provided by an increased mutation rate during tumour evolution 11, 12 .
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(TABLE 1). These mechanisms involve the DNA repair processes themselves, the systems that regulate and organize them, and the systems that integrate DNA damage repair with the cell cycle 2 . Disruption of the DDR is observed in many can cers [3] [4] [5] and it underlies the genomic instability that accompanies tumorigenesis and progression. However, in most cases, the specific underlying defects are poorly characterized 6, 7 . Conversely, there are welldescribed cancers in which disruption of a DDR mechanism is directly causal. For example, Lynch syndrome (also known as hereditary nonpolyposis colorectal can cer (HNPCC)) is associated with lossoffunction mutations in mismatch repair (MMR) genes -most commonly mutS homologue 2 (MSH2) and mutL homologue 1 (MLH1) 8 . Current theories propose that DDR defects in tumour development and progression are positively selected by the need to tolerate oncogene induced replication stress 9, 10 and/or by the adaptive advantage provided by an increased mutation rate during tumour evolution 11, 12 .
Although DDR defects are causative and permis sive of disease, they can provide a weakness that can be exploited therapeutically [13] [14] [15] [16] . Genotoxic drugs that cause DNA damage exceeding the repair capacity of DDR sys tems have been the mainstay of cancer chemotherapy for over 30 years. These include drugs that alkylate bases (for example, temozolomide) 17 , that covalently crosslink DNA strands (for example, cisplatin) 18 or that cleave the sugar-phosphate backbone (for example, bleomycin) 19 . There are also drugs for approximately ten protein targets that modulate the DDR indirectly (FIG. 1; see Supplementary information S1 (table)), albeit mostly through genotoxic effects. These drugs include inhibitors of proteins involved in DNA synthesis (for example, DNA polymerases), proteins that regulate epigenetic control (for example, DNA methyltrans ferase 1 (DNMT1)) and proteins with an indirect role in DNA replication (for example, topoisomerases).
In addition to these licensed drugs, there are a number of compounds currently under clinical evaluation that tar get DDR pathways directly. These targets include the pro tein kinases that are involved in cell cycle DNA checkpoints that are induced by DNA damage and/or replicative stress (for example, checkpoint kinase 1 (CHK1) and WEE1), as well as individual enzymes involved in base excision repair (BER; such as apurinicapyrimidinic endonuclease 1 (APEX1)), direct repair (such as 6OmethylguanineDNA 1 methyltransferase (MGMT)), nonhomologous end joining (NHEJ; such as DNAdependent protein kinase (DNAPK)) and telomere maintenance (such as telomer ase reverse transcriptase (TERT)).
The initial rationale for the development of DDR enzymetargeted drugs focused on their use as poten tiators, inhibiting the repair of damage caused by radiotherapy and/or conventional genotoxins 15 . However, this approach has been extended to stand alone use: targeting DNA repair pathways that are critical to tumour cell survival by exploiting synthetic sensitivity or lethality (SSL) 20 . Synthetic lethality arises when a combination of loss of function in two or more genes leads directly to cell death, whereas loss of 95 Homologous recombination HR (DS) 52 The broken ends of a DSB are resected to allow invasion of the single strands into a sister chromatid, which functions as a template for accurate re-synthesis of the damaged DNA to facilitate error-free DSBR 96, 97 Non-homologous end joining NHEJ (DS) 27 NHEJ ligates DSBs. It does not require a template strand to facilitate DSBR 98 Base excision repair BER (SS) 42 Monofunctional and bifunctional DNA glycosylases and endonucleases excise damaged bases and abasic sugars following spontaneous deamination, oxidation or alkylation to form SSBs. SSBs also arise spontaneously from DNA backbone damage induced by ROS. DNA polymerases and DNA ligases are then used to fill and ligate the broken strand 99 . In BER, after the base and the sugar have been removed, the downstream process is also described as SSBR.
Direct repair DR (SS) 3
A group of proteins that directly repair damaged DNA bases. There are three common types of lesion repaired: O
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-methylguanine, 1-methyladenine and 3-methylcytosine 100 Mismatch repair MMR (SS) 27 MMR corrects replication errors that cause the incorporation of the wrong nucleotide (a mismatch) and nucleotide insertions and deletions 101 Nucleotide excision repair NER (SS) 66 NER removes helix-distorting and bulky adducts on DNA: for example, those caused by UV radiation and tobacco 102 Translesion synthesis TLS 19 If damaged DNA bases or adducts are not repaired before replication has initiated, they may stall replication forks, contributing to genetic instability 103 . Specialized TLS DNA polymerases are recruited to synthesize the DNA at these sites
Associated pathways
Chromatin remodelling CR 29 Chromatin remodelling enables dynamic access to DNA 104 Telomere maintenance TM 28 Telomeres are the physical ends of chromosomes responsible for chromosome end protection. A capping structure prevents the exposed ends of DNA being 'repaired' by DSBR and prevents otherwise exposed ends of different chromosomes from becoming fused together 105 Checkpoint factor CPF 54
The DDR requires integration with other cell cycle processes through checkpoint signalling to allow time for repair to prevent DNA damage being made permanent by replication and mitosis 106 Ubiquitin response UR 29
The DDR involves a signalling cascade that uses many forms of post-translation modification of proteins, including phosphorylation and ubiquitylation. Ubiquitylation is used to target proteins for proteasomal degradation and is also involved in the regulation of protein function and in mediating complex assemblies 107 p53 pathway p53 9 Inclusion of genes in the p53 apoptosis pathway that are involved in mediating the DDR 108 Chromosome segregation CS 16 HR is dependent on the sister chromatid and works in partnership with the chromosome cohesion machinery to ensure that defects are repaired before mitosis takes place. The chromatids are held together by cohesin until mitosis, facilitating HR 109 This table is split into classical DNA repair pathways and associated pathways. Although members of the DNA repair pathways are as comprehensive as possible, for the associated pathways only the subset of genes most integrated with the DNA damage response have been included in our analysis. Not all of the genes in our data set have been assigned to one of these pathways, and genes may have membership of more than one pathway. DS, double-strand DNA; DDR, DNA damage response; DSB, DNA double-strand break; DSBR, DSB repair; ROS, reactive oxygen species; SS, single-strand DNA; SSB, single-strand DNA break; SSBR, SSB repair; UV, ultraviolet. DS and SS indicate whether one strand (SS) or both strands (DS) are modified during the repair process. *The full classification of every gene in the data set is in Supplementary information S3 (table) . ABL1  DNMT1  PARP1  PARP2  PARP3  POLA1  RRM1  RRM2  RRM2B  TOP1  TOP2A  TOP2B  TYMS   Target   Ligands   0   1,000   2,000 3,000 APEX1  ATR  CDK2  CDK4  CHK1  CHK2  MDM2  MGMT  mTOR  PRKDC  TERT  p53  WEE1   a   c   b   ATM  BRCA1  CDC25A  CDC25B  CDK7  CDKN1A  CLK2  CSNK1D  CSNK1E  DUT  ERCC5  FANCF  FEN1  LIG1  MDM4  MEN1  NPM1  PARG  PARP4  POLB  POLD  PRKCG  RAD51  SIRT1  TDP1  TNKS 
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Polymerase function in only one of the genes does not. Synthetic sensitivity results in impaired cell growth or prolifera tion, which may lead to cell death in the presence of additional stresses or additional therapeutic insults, such as ionizing radiation or cytotoxic chemotherapy. In practice, SSL responses are likely to be on a spec trum, with the ideal being singleagent lethality. The therapeutic aim is to exploit genetic defects that are essential to tumour cell survival by combining the defect in an affected pathway with a pharmacologically induced defect in a compensating pathway 21 .
The best example of a drug regime that exploits SSL relationships is the pharmaceutical inhibition of poly(ADPribose) polymerase 1 (PARP1) 13 . PARP1 is a key enzyme in singlestrand DNA break repair (SSBR), inhibition of which is synthetic lethal with defects in the genes that encode the homologous recombination (HR) proteins BRCA1, BRCA2 and partner and local izer of BRCA2 (PALB2); these defects are observed in a proportion of sporadic and familial highgrade serous ovarian adenocarcinomas 22 , as well as heredi tary breast, ovarian, pancreatic and prostate cancers (known as HBOC syndrome). The furthest progressed PARP inhibitor, olaparib (also known as AZD2281), has recently (December 2014) been approved by the US Food and Drug Administration (FDA) for use in women with heavily pretreated ovarian cancers that are associated with defective BRCA genes, and by the European Medicines Agency as a maintenance therapy in BRCAmutated (germline or somatic) platinum sensitive, advanced ovarian, fallopian tube or primary peritoneal cancers. Efforts are also underway to expand the use of PARP1 inhibitors into a broader range of cancer types displaying defects in HR 23 . To help identify new therapeutic opportunities within the DDR, we have assembled a comprehensive data set of DDR proteins, classified by the molecular processes in which they occur. We have assessed them systemati cally using a range of bioinformatics and chemogenomic approaches to define their involvement in oncogenesis and to identify their suitability for functional inhibition by small molecules. Unlike the protein kinase signalling pathways that have been the focus of much anticancer drug development in the past 24 , DDR proteins have diverse structures and functions, and major efforts in target identi fication and validation are needed before they can be fully exploited. Moreover, because many cancerassociated mutations of DDR proteins are lossoffunction muta tions rather than activating mutations (as is the case with kinases) 25, 26 , a systems biology approach is needed to iden tify the best targets, which often will not be the mutated protein itself. The ultimate aim of this study is to identify 'druggable' points of intervention within the DDR network on which drug discovery might be effectively focused.
Assignment of proteins to DDR processes
We compiled a data set of 450 genes encoding proteins that are integral to the DDR (see Supplementary infor mation S2,S3 (box, table)) using several strategies. First, a panel of experts on the core DDR pathways defined the key genes within their pathway (or pathways) of expertise. This list was expanded by entries in pathway databases (for example, Kyoto Encyclopedia of Genes and Genomes (KEGG) 27 and Reactome
28
; see Further information) that are annotated as belonging to DDR processes. Proteins that functionally or physically interact with this set of gene products were identified using STRING 29 , and their candidacy for inclusion was assessed by Gene Ontology terms 30 and by consulting the literature. The expanded list was rereviewed by the experts, and omissions and misinclusions were rectified.
The complete list includes genes involved in 'core' DDR activities, such as BER, MMR, HR and NHEJ. However, this core machinery does not function in isolation: it is integrated with complementary processes that are essen tial to overall genome maintenance. Consequently, we have also included proteins that are not directly involved in DNA damage sensing or repair but that are required for regulating or facilitating the DDR and that may therefore provide viable druggable intervention points for modu lating the DDR. TABLE 1 summarizes the major processes included, with the number of genes involved in each.
Core DDR pathways. These core pathways are a set of functionally distinct, intertwined pathways, defined historically by the biochemical mechanism that they use to achieve repair. Each typically includes a series of ordered processes comprising the detection of DNA damage, recruitment of proteins to the site of the damage and repair of the physical lesion. These core pathways include those that directly reverse DNA damage, that excise mismatched and chemically modified bases and nucleotides, and that repair singlestrand DNA breaks (SSBs), doublestrand DNA breaks (DSBs), intrastrand crosslinks and interstrand crosslinks.
The core pathways also include tolerance mecha nisms that confer viability in the presence of unrepaired DNA damage. The best described of these, translesion synthesis (TLS), consists of a set of specialized DNA polymerases and regulatory proteins that allow replica tion across template lesions that would otherwise block the progress of replicative DNA polymerases. In the absence of TLS, unrepaired lesions cause replication fork collapse, generating singleended DSBs that promote illegitimate HR and aneuploidy.
Processes facilitating the DDR. The processes that facilitate the DDR include chromatin remodelling, which enables access to DNA damage, and chromo some cohesion and alignment, which ensure legitimate HR between sister chromatids. Telomere maintenance acts as a barrier to genomic instability by preventing inappropriate involvement of chromosome ends in recombination events.
Repair of 'architectural' damage, such as DSBs or crosslinks, also requires the integration of cell cycle control via DNA damage checkpoint signalling to allow time for repair and to prevent cells from entering mito sis with substantial unrepaired damage. Consequently, checkpoint factor (CPF) proteins are included in the data set. Similarly, many proteins involved in the ubiquitylation response (UR) are included owing to their roles in mediating DDR complex assembly and disassembly. Topoisomerases and the enzymes that release stalled topoisomerases are also included because their modulation affects the DDR response. A general category encompasses those proteins that are strongly implicated in an effective DDR but that are not identified as components of one of the processes mentioned above.
We devised a hierarchical classification that assigns proteins to the pathways, processes and complexes to which they contribute (see Supplementary infor mation S3 (table) ). For instance, several proteins involved in DSB repair (DSBR) could be assigned to the Fanconi anaemia pathway (FA), HR or NHEJ. At the next level, proteins were assigned to the func tional complexes in which they participate; that is, FA proteins could be assigned to the FA core complex or to the Bloom's syndrome complex, among others. Proteins were not limited to a single assignment, and if they were involved in more than one process, they were assigned to each one.
DDR protein interaction network
Although many DDR processes can be considered as linear pathways, the proteins involved often par ticipate in multiple complexes and may have differ ent roles in different processes. Furthermore, pathway definitions are incomplete because new genes (for example, REF. 31 ) and new roles for existing genes (for example, REF. 32 ) are still being elucidated. We have therefore sought to develop a systems biology repre sentation of the DDR, which provides a more holistic view of the integration and interdependencies of DDR processes. Nature Reviews | Cancer , an interactive file generated using Gephi (see Further information)). Although most DDR proteins occur within a single pathway (86%), over half (56%) interact with proteins that are involved in other DDR pathways. This high level of interconnectedness presents potential challenges for pharmacological inter vention because inhibition of a target aimed at disrupting one DDR mechanism may affect several systems and may thus generate unanticipated toxicities. However, in other 87 . This algorithm brings mutually interconnected proteins within the same pathway (for example, nucleotide excision repair (NER) or homologous recombination (HR)) into distinct clusters, whereas proteins in systems such as non-homologous end joining (NHEJ) and mismatch repair (MMR), which have multiple interactions with other systems and pathways, are more diffusely distributed across the network. Nature Reviews | Cancer circumstances, affecting multiple systems may be advan tageous. A systems biology view of the interconnectedness of DDR pathways will be critical to understanding the cellular response to DDRdirected drugs and will help to elucidate mechanisms of resistance that are not yet clearly understood.
Functional characterization
The discovery of smallmolecule modulators of new classes of target is particularly challenging, and it is much easier to identify hits for classes of proteins that have already been successfully drugged. We therefore compared the classes of proteins comprising the DDR with those already successfully targeted in cancer generally to identify the most tractable opportunities. We classified the DDR proteins into major functional classes (FIG. 3a) . Enzymes constituted 40%; scaffold pro teins (or noncatalytic components of a multiprotein catalytic complex) 24%; enzyme regulators 6%; and transcription factors and regulators 9%. The major enzymatic classes were helicases (7%), ubiquitin ligases (5%), nucleases (5%) and polymerases (5%), with pro tein kinases constituting just 4%. The proportion of enzymes in the DDR (40%) is lower than the propor tion of enzymes that are approved drug targets across all therapeutic areas (~50%) 33 and substantially lower than the proportion of enzymes that are general cancer targets (~60%; FIG. 3a) 
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; however, the proportion of enzymes in the DDR is higher than the proportion of cancercausing genes that encode enzymes (25-30%) 35 . The distribution of enzymatic classes in the DDR differs markedly from the distribution in current cancer targets. Over one third (38%) of cancer targets with approved drugs are protein kinases, but these constitute a minor fraction of the DDR. Conversely, helicases, for which there are no currently licensed drugs, constitute 7% of the DDR. , table) ). 7TM, seven transmembrane; AML, acute myeloid leukaemia; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma; COAD, colon adenocarcinoma; GBM, glioblastoma; KIRC, kidney renal clear cell carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; OV, ovarian serous carcinoma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; UCEC, uterine corpus endometrial carcinoma.
Consistent with their biological role, the vast majority (97%) of DDR proteins display strong nuclear localiza tion, in contrast to only 10% of the current portfolio of current cancer targets. Although small molecules can traverse nuclear pores without difficulty, different drug chemotypes may be needed if high nuclear concentra tions are required for effective inhibition of the DDR. In a similar vein, the large amount of DNA in the nucleus and the consequently high concentration of offtarget intercalation and minor groove binding sites for basic and/or planar molecules may present unanticipated challenges for drug availability.
Disease association of DDR proteins DDR processes maintain genomic integrity and regu lated cellular function, so defects in DDR genes are frequently associated with diseases, including cancer (see Supplementary information S5 (table)). Of the 450 DDR genes in this analysis, defects in more than one quarter are associated with human disease. These genes are not restricted to specific DDR systems but are widely distributed throughout the DDR.
Germline defects in 58 genes are linked to inher ited cancer predisposition or to cancerassociated syndromes, and 42 are linked to inherited syndromes that are unrelated to cancer. Several DDR genes that are associated with familial cancer predisposition syn dromes owing to inactivating germline mutations (for example, TP53 (which encodes p53), MSH6, MSH2, MLH1, ataxia telangiectasia mutated (ATM), SMARCB1 and cyclindependent kinase inhibitor 2A (CDKN2A)) are also frequently somatically mutated in various can cers, emphasizing their tumour suppressive roles and highlighting the DDR pathways in which they partici pate as being crucial for maintaining genomic stability. However, other tumour suppressors such as BRCA1 and BRCA2, defects in which have strong germline associa tions with familial cancers, are only rarely found to be mutated in somatic cancers, although they are more fre quently epigenetically silenced 22 . In some cases disease presentation depends on whether germline mutations are heterozygous or homozygous. Thus, heterozygous lossoffunction mutations in BRCA2 or PALB2 predis pose to earlyonset breast 36 , ovarian 37 , prostate 38, 39 and pancreatic cancers 40 , whereas homozygous mutations in these genes manifest as Fanconi anaemia 41 . Mostly, DDR defects that are implicated in cancer predisposition, genetic diseases and somatic cancers arise from mutations causing a loss of function of the protein product 25, 42 . Further analysis of somatic muta tion patterns in these genes 4,43 using the 20:20 rule 3,44 pre dicts a fivefold enrichment in tumour suppressors over oncogenes (see Supplementary information S6 (table)). Identifying potentially druggable targets within the DDR is challenging because we predict that the majority of DDR genes are more likely to function as tumour sup pressors and not as the activated gene products that are more conventionally targeted in cancer drug discovery. Rarely, it may be feasible to directly reactivate a muta tionally inactivated tumour suppressor. Posttranslational reactivation (rather than transcriptional reactivation of an epigenetically silenced tumour suppressor) requires that the inactivating mutation does not ablate the protein product but generates an altered form, the biochemical function of which can be restored by binding of a stabi lizing or modifying ligand. This approach is primarily being explored in the context of destabilizing mutations of TP53 (reviewed in REF. 45 ): in such cases, restoration of p53 function could trigger apoptosis of tumour cells that have extensive DNA damage.
The alternative strategy that we explore in detail below is the identification of other gene products, within and outside the DDR, for which loss of function is not itself lethal to a cell but becomes so in the presence of a cancerassociated mutation in a DDR component (SSL).
DDR deregulation in patients
Because inactivation of DDR pathways typically leads to increased genomic instability -a hallmark of car cinogenesis and cancer progression -we looked at the frequency with which these genes are mutated, are significantly overexpressed or underexpressed, or show copynumber alterations in a range of cancers using data from The Cancer Genome Atlas (TCGA; see Further information) 4, 46, 47 . Our analysis shows that 95% of DDR genes catalogued in our curated list had coding region mutations (that is, missense, frameshift, insertion, dele tion or nonsense mutations) within the 15 cancers stud ied. The level of mutation observed reflects the genetic instability of the individual tumour, and not all of the mutations will contribute to the cancer phenotype. On average, each patient accrued 3.12 coding mutations in DDR genes, but the averages differed considerably between cancer types.
The cancer types with the most DDR mutations were those associated with known mutator pheno types. Colorectal cancers, which commonly have MMR defects, had the highest frequency of DDR gene muta tions with an average of 11.44 DDR mutations per patient. Similarly, uterine corpus endometrioid carci noma 48 had a very high level of mutations in DDR genes (7.69 mutations per patient). Many of the endometrial tumours had mutations of the proofreading DNA poly merases POLE or POLD1, which may reduce the fidelity of DNA replication, and they also had a high level of MMR mutations. The lung cancers analysed (squamous cell and adenocarcinoma) also exhibited a high number of DDR mutations (3.93 mutations per patient), reflect ing the large proportion (>75%) of tobacco smokers in the cohorts sequenced. Smokers often display a high level of C→A transversions 49 , particularly in methylated CpG dinucleotides 50 , due to the mutagenic effects of tobacco smoke, and these mutations often accumulate before the onset of disease 51 . The cancer types with the lowest numbers of DDR gene mutations included acute myeloid leukaemia (AML) and glioblastoma 52, 53 , which had less than one DDR gene mutation on average (0.70 and 0.97 mutations per patient, respectively). The mutational frequencies in the DDR genes are assumed to reflect the mutational frequencies observed across the complete genome and are characteristic of individual disease; however, most of the cancers analysed here are enriched for DDR proteincoding mutations (FIG. 3c; see Supplementary information S7 (table)), suggesting that DDR disrup tion is important in these cancers. AML, ovarian cancer and glioblastoma are the most enriched in DDR coding mutations, although the total number of mutations may be low. Cancer types that do not exhibit enrichment for DDR gene mutations include cervical squamous cell carcinoma, which usually has a viral aetiology involving viral proteins disabling tumour suppressors, and lung cancers, in which genomewide mutations accumulate owing to carcinogen exposure before disease onset.
In the six cancers for which we had cancer-normal matched expression data (bladder urothelial carcinoma, breast invasive carcinoma, head and neck squamous cell carcinoma (HNSC), liver hepatocellular carcinoma (LIHC), lung adenocarcinoma and lung squamous cell carcinoma; see Supplementary information S7 (table)), on average there was a threefold increase in the num ber of DDR genes overexpressed (2.7%), compared with an equivalent set of nonDDR genes (0.74%) (see Supplementary information S7 (table)). Taken together, these data suggest that the genomic instabil ity resulting from mutational damage and functional impairment in one part of the DDR may promote the upregulation of compensatory pathways in other parts of the global DDR system. Using these data, and copynumber alterations, we identified the genes disrupted (defined as mutated or showing alterations in copy number or expression level) in each DDR process (see Supplementary information S8 (table)) for the 15 cancer types studied to generate DDR pathwaybased disruption signatures for each cancer (FIG. 4) . A gene was considered to be disrupted if the anomaly was observed in at least two patients.
We found that every DDR process was function ally impaired to some extent in one or more cancer type. However, the types of DDR process impaired, and how often these defects were observed in patient sam ples, differed among cancer types. Some cancers are restricted in the processes disrupted, whereas others are surprisingly heterogeneous, with different pathways and combinations of pathways varying in different patients. In glioblastoma, mutations concentrate in p53 pathway genes and CPFs, with a far lower frequency observed in other DDR processes. In AML, mutations are concentrated in chromosome segregation genes and genes that are involved in DSBR but that are not assigned to a canonical repair pathway (classified as 'other DSR'), which includes the gene encoding nucle ophosmin (NPM1) -a major prognostic biomarker in AML that has been implicated in DSBR as well as a range of other nuclear functions 54 . Conversely, colon adenocarcinoma 55 has mutations in all DDR processes. These signatures also define patterns of disruption. For example, although colorectal cancers are often asso ciated with MMR defects, a similar proportion have HR defects. Furthermore, the relative proportions of DDR mutations in pathways in lung and bladder cancers mirror those found in colon cancer, although lung and bladder cancers show far fewer DDR gene mutations overall. This suggests that the stratification of DDR disruption subtypes in these diseases could ultimately lead to more effective targeted therapy, with differ ent patterns of disruption being treated with different therapeutic regimes.
SSLs within the DDR
Apart from attempts to stabilize mutant p53 (REF. 56 ), direct targeting of the defective products of mutated DDR genes is unlikely to have therapeutic benefit. Instead, therapeutic interventions must be targeted towards other proteins with functions that are mostly dispensable in normal cells but that become essential (or at least important) in the genetic context of the DDR mutation -thus providing SSL. The challenge then for effectively exploiting the plethora of DDR mutations in cancers is the identification of SSL counterparts of diseaseaffected DDR proteins or pathways and the development of a nontoxic smallmolecule modulator of that counterpart protein or pathway.
The exquisite sensitivity to pharmacological dis ruption of SSBR through inhibition of PARP1 in HRdeficient tumours is the best established example of SSL 57 . Although this singleagent lethality may be an extreme example that results from the inherent back ground occurrence of SSBs in all cells, experience in dissecting DDR pathway interactions in model organ isms and cell systems suggests that there will be many opportunities to exploit cytostatic and cytotoxic SSL relationships in tumours with diverse genetic profiles. Other reported SSL examples include small interfering RNA (siRNA)mediated knockdown of POLB in an MSH2deficient background and inhibition of POLG in an MLH1deficient background 58 . Because the MLH1 and MSH2 proteins are mutationally inactivated in a high proportion of bowel cancers, inhibitors of these DNA polymerases could have a widespread clinical impact 23 . Opportunities for SSL may also occur between DDR systems and other cellular regulatory apparatus, as well as between the different DDR pathways.
Yeast genetic interaction screens have been used to predict SSL partners of human cancer genes 59 . To iden tify putative DDR SSL pathway interdependencies in humans, we identified published yeast negative genetic interactions using BioGrid 60 and mapped the corre sponding human orthologues onto them. FIGURE 5a shows the predicted SSL relationships of human DDR orthologues, grouped by pathway (the predictions are detailed in Supplementary information S9 (figure), an interactive file generated using Cytoscape (see Further information)). These indicate multiple SSL interdepend encies between the major pathways that have the poten tial to be exploited therapeutically. However, there are limitations to this method in that only 54% of human DDR genes have yeast orthologues, and it is not known exactly how many genetic interactions are conserved between humans and yeast (for a review, see REF. 61 ).
As expected from the severe consequences of unre paired DSBs, HR and NHEJ pathways show a high level of SSL with many other pathways. The major cluster of SSL relationships occurs between HR and nucleotide Nature Reviews | Cancer . The radial extent indicates the proportion of patients analysed for each cancer type who had non-silent protein-coding mutations in a component of the DDR pathway, arrayed circumferentially, that could disrupt the function of that pathway. Only genes mutated in at least two different patient samples were considered, and mutation of multiple proteins in the same patient in the same pathway counted as a single pathway disruption. Numbers of patients in each study are indicated. Concentric circles indicate the percentage (10%, 30%, 50% and 70%) of patients affected (see Supplementary information S2 (box) for details and Supplementary information S8 (table) for underlying data). b | Copy-number variation in different DDR pathways. Inclusion criteria were the same as for part a; concentric circles indicate the percentage (10%, 30% and 50%) of patients affected. Red indicates loss of gene copies; blue indicates amplification. c | Expression level variation in different DDR pathways. Inclusion criteria were the same as for part a, with at least a twofold change in level required; concentric circles indicate the percentage (10%, 30% and 50%) of patients affected. Red indicates decreased expression; blue indicates increased expression. AM, alternative mechanism for telomere maintenance; BER, base excision repair; CPF, checkpoint factor; CR, chromatin remodelling; CS, chromosome segregation; DR, direct repair; FA, Fanconi anaemia pathway; HR, homologous recombination; MMR, mismatch repair; NER, nucleotide excision repair; NHEJ, non-homologous end joining; OD, other double-strand break repair; TLS, translesion synthesis; TM, telomere maintenance; UR, ubiquitylation response. Nature Reviews | Cancer . The size of each node reflects the number of human proteins assigned to that system; edge-widths are in proportion to the number of negative genetic interactions observed in the yeast data. b | Network representation of predicted synthetic lethalities between human DDR genes, based on experimentally determined negative genetic interactions between yeast orthologues of the components of each pathway or system. The network has a BioLayout generated by Cytoscape 94 . Only genes with cancer-associated protein coding mutations that show SSL with topoisomerase 1 (TOP1), checkpoint kinase 2 (CHK2), CHK1 and cyclin-dependent kinase 4 (CDK4) are displayed. Targets with licensed inhibitors (TOP1) or that are in clinical trials (CHK1, CHK2 and CDK4) are shown in red. Genes with protein-coding mutations are shown in blue. The darker the shade of blue, the higher the number of cancer types in which these genes are mutated in more than 1% of patients. ACTR8, ARP8 actin-related protein 8 homologue; BER, base excision repair; CNOT7, CCR4-NOT transcription complex, subunit 7; CPF, checkpoint factor; CR, chromatin remodelling; CS, chromosome segregation; EXO1, exonuclease 1; FA, Fanconi anaemia pathway; FEN1, flap structure-specific endonuclease 1; HR, homologous recombination; KAT2A, lysine acetyltransferase 2A; MMR, mismatch repair; NCAPD2, non-SMC condensin I complex, subunit D2; NCAPH, non-SMC condensin I complex, subunit H; NER, nucleotide excision repair; NHEJ, non-homologous end joining; PAPD7, PAP-associated domain containing 7; PBRM1, polybromo 1; POLD1, DNA polymerase δ1; PPP6C, protein phosphatase 6, catalytic subunit; RFC5, replication factor C5; SMC2, structural maintenance of chromosomes 2; TLS, translesion synthesis; TM, telomere maintenance; TOP2B, topoisomerase 2β; UR, ubiquitylation response; XPA, xeroderma pigmentosum, complementation group A.
The complexity of the SSL relationships again highlights the poorly understood interconnectedness of the canoni cal pathways and the intricate relationships between their component proteins.
The SSL data identify several opportunities for using existing therapies in novel genetic backgrounds (FIG. 5b) . For example, the topoisomerase 1 (TOP1) inhibitors irinotecan and topotecan are used in first line treatment of colorectal cancers in combination with 5fluorouracil, and as secondline treatment for ovary, cervix and smallcell lung cancers in com bination with cisplatin. In yeast, the homologues of TOP1 and polybromo 1 (PBRM1) show SSL. PBRM1 is mutated in 24% of kidney and 3.5% of all cancers. If this SSL relationship is conserved in humans, a TOP1 inhibitor might be effective in cancers with defective PBRM1. Similarly, our analysis predicts that CHK2 inhibitors will have utility in MSH2defectve tumours, which account for 8% of colorectal cancers and 1% of all cancers. The data also reveal some new potentially druggable targets (discussed in more detail below), including MRE11 (in an MSH2deficient background) and antisilencing function 1B histone chaperone (ASF1B; in a PBRM1deficient background).
There are many other druggable targets, such as flap structurespecific endonuclease 1 (FEN1), Werner syndrome, RecQ helicaselike (WRN) and RAD52, the yeast homologues of which show SSL with homo logues of a range of less frequently mutated cancer genes (see Supplementary information S9,S10 (figure, table); S9 is an interactive file). Many of the observed SSL relation ships can be rationalized biochemically owing to the high degree of interconnectedness of DDR pathways (FIG. 2) , although few of them would be predicted ab initio.
Expanding druggable opportunities in DDR
To establish whether targeting DDR proteins does indeed offer new therapeutic opportunities, we used several complementary strategies to try to determine the inherent druggability of DDR proteins. By combin ing SSL data with the careful analysis of individual DDR pathways, we have identified a range of tractable targets for each DDR pathway.
DDR proteins with small-molecule modulators.
Using the target annotation tools in canSAR 63 , based on data from ChEMBL 64 , we identified compounds with submicro molar activity and/or affinity for 53 of the 450 DDR tar gets, including 38 with druglike, 'rule of five'compliant compounds 65 ( FIG. 1; see Supplementary information S11 (table)). Of these DDR targets, 26 have compounds that are approved or under clinical evaluation. However, 27 targets are still in the discovery phase, with no mol ecule yet advanced to clinical study, but these potentially represent the next generation of DDR targets. Of these 27 discovery targets, seven (ATM, cyclindependent kinase 7 (CDK7), deoxyuridine triphosphatase (DUT), CDClike kinase 2 (CLK2), ERCC5, FEN1 and DNA ligase 1 (LIG1)) have orthologues involved in SSL rela tionships in yeast that may indicate genetic backgrounds in which compounds might have clinical utility.
Assessment of the druggability of DDR proteins. Using the canSAR 63 knowledgebase, we have utilized several meth ods to estimate the tractability of the DDR proteins as potential drug targets. We estimated DDR protein drug gability based on the chemical properties and bioactivity of small molecules annotated in the ChEMBL 64 database using a ligandbased assessment protocol 63 . We identified 216 proteins incorporating domains where homologues have previously been tested for interaction with chemi cal matter, of which 107 (including ERCC4, Xray repair crosscomplementing protein 5 (XRCC5), FANCD2/ FANCIassociated nuclease 1 (FAN1), SMARCA2, death domain associated protein (DAXX) and structural main tenance of chromosomes 4 (SMC4); see Supplementary information S12 (table)) were predicted to be druggable.
We also used a structurebased assessment method 64, 66 that identifies cavities on the surface of a protein struc ture and assesses their probable druggability based on physiochemical parameters independent of the homol ogy of the protein to known drug targets. The impor tance of the DDR is reflected in a high level of interest from structural biologists, with over half (246; 55%) of the DDR gene products having been structurally characterized to some degree. This set of proteins can be expanded further for druggability analysis by identifying structurally characterized close homologues.
Of the 291 proteins with experimental structures, or a closely homologous structure (greater than 50% sequence identity), 38% (175) are predicted to contain druggable binding sites using the DrugEBIlity 64 algorithm, includ ing polynucleotide kinase3′phosphatase (PNKP), WRN, INO80, DNA crosslink repair 1B (DCLRE1B; also known as Apollo) and PIF1 (see Supplementary informa tion S13 (table)). Examining druggability by functional class confirms the expectation that enzymes are the most likely targets, with 72% considered druggable, although over half (53%) of scaffold proteins are also predicted to contain druggable binding sites.
Representation of the DDR network as a system of functional nodes connected by identified proteinprotein interactions allows the application of network analysis techniques to predict key druggable interven tion points. Using canSAR 63 , reliable network drug gability predictions could be made for 374 proteins with sufficient experimentally determined protein interactions. Of these, 105 were deemed druggable on the basis of network environment profiles that were similar to those of known cancer targets. There were significantly fewer candidates (p = 0.03) identified than expected, probably reflecting the pathway structure of the DDR, which differs considerably from the signal ling pathways more commonly drugged. Proteins occu pying the most druggable network positions include RAD51, DNA damagebinding protein 1 (DDB1), POLD3, SMARCA5, menin (MEN1) and HUS1 (see Supplementary information S14 (table)) .
Proteins predicted to be druggable by each of these methods are highlighted on the DDR protein inter action network (Supplementary information S15 (figure) , an interactive file generated using Gephi (see Further information)).
Targeting proteins that regulate the DDR As well as assessing proteins within the DDR, we have explored the set of proteins outside the 'core' that are known to regulate DDR activity.
Protein kinases regulating the DDR. Many DDR pro cesses are regulated by phosphorylation, so protein kinases -a highly druggable class of proteins -are attractive targets for pharmacological modulation of DDR function. Considerable effort has already been expended on developing inhibitors of protein kinases that regulate DDR processes. These include the damage sensing PI3Klike kinases ATM, ataxia telangiectasia and Rad3related (ATR) and DNAPK, and the checkpoint kinases CHK1 and CHK2 (see Supplementary informa tion S1 (table)), as well as kinases that are specifically involved in mitosis and chromosome segregation, such as aurora kinase B (AURKB) 67 and pololike kinase 1 (PLK1) 68 . Using the PhosphoSitePlus 69 database, we identified 82 kinases phosphorylating 141 DDR proteins (see Supplementary information S16 (table) ). Of these, 18 kinases phosphorylate at least ten DDR components or have DDR components as the majority of their known substrates. In addition to the DNA damagesignalling kinases, the search identified CDK1, CDK2, glycogen synthase kinase 3β (GSK3β) and casein kinase 2 (CK2), which phosphorylate proteins in many cellular processes as well as the DDR, meaning that specific modulation of the DDR would not be achievable by this route. A small number of more 'specific' phosphorylation sites that are dependent on kinases not normally associated with the DDR were identified; however, the biological importance of these remains to be determined. DDR regulation by ubiquitin. Like phosphorylation, ubiq uitylation has important roles in the regulation of DDR systems, both as a posttranslational modification that regulates complex assembly and as a mark for degrada tion through the ubiquitin-proteasome system. Indeed, a number of DDR proteins with clear cancer associations (for example, BRCA1 and FANCL) are themselves E3 ubiquitin ligases. Although the knowledge base for ubiq uitylation is far less well developed than that for phospho rylation, more than 311 of the 450 proteins in our set of DDR proteins have been reported to be subject to ubiqui tylation of one sort or another, and 36 are also reported to be subject to modification by the ubiquitinrelated SUMO (small ubiquitin modifier) protein (see Supplementary information S17 (table) ). This widespread involvement of ubiquitin (and SUMO) modifications in DDR regula tion suggests that this system may offer opportunities for therapeutic intervention in cancer 70 .
The main druggable opportunity lies in the inter action between E3 ubiquitin ligases and their target proteins, which are often limited to a focal interaction of a peptide motif with a pocket or channel. One of the best examples of this type is the interaction of the E3 ubiquitin ligase MDM2 with the DNA damagesignalling protein p53, the loss or downregulation of which is observed in most cancers. Blocking the MDM2-p53 interaction prevents p53 degradation and can restore apoptosis in tumours with wildtype p53. A range of smallmolecule inhibitors of this interaction are being evaluated clinically 45 . We identified 24 druggable E3 ubiquitin ligases within our core set of DDR proteins, and a further 16 that interact with DDR proteins and may warrant further investigation (see Supplementary information S2,S18 (box, table)).
The enzymes that remove ubiquitin modifications of DDR proteins have also come under the spotlight as potential targets for smallmolecule therapeutics in cancer (reviewed in REFS 71, 72) . These deubiquitylating enzymes (DUBs), of which ~100 are identifiable in the human genome, hydrolyse the isopeptide bond linking the carboxyterminal Gly of ubiquitin with a Lys side chain on the target protein or another ubiquitin molecule. Ubiquitinspecificprocessing protease 1 (USP1), which deubiquitylates proliferating cell nuclear antigen (PCNA) and FANCD2, and USP7, which deubiquitylates MDM2, p53 and a range of proteins involved in BER, NER and DNA damage checkpoint signalling, have been at the fore front of drug discovery for this class of enzymes 73, 74 . There are 37 DUBs reported to interact with DDR proteins (see Supplementary information S19 (table)), of which 23 are predicted to be druggable and of which two had reported inhibitors. Individual siRNAmediated knock down of any of ten DUBs, including USP20, ubiqui tin Cterminal hydrolase isozyme L5 (UCHL5) and USP3, reduced the efficiency of DSBR 75, 71 . Despite these interesting preclinical observations, a clear clinical application for DUB inhibitors in cancer is yet to emerge.
Identification of novel DDR targets
Using a combination of methods, including druggability predictions, predicted and reported human SSL relation ships and analysis of the DDR pathways, we have iden tified tractable targets for each of the DDR processes. 76 . FEN1, a DNAflap endonuclease, is involved in BER, and inhibiting it would probably show SSL with the HR defects observed in HBOC syndrome. A number of structurally diverse smallmolecule FEN1 inhibitors have been described [77] [78] [79] , but all contain at least one important structural alert and are not attractive starting points for medicinal chemistry. Hits have been identified in a recently reported screen, but no details of the compounds have been disclosed 80 . Other potentially druggable endonuclease or exonuclease targets include DCLRE1B, MUS81 and ERCC4 (TABLE 2) .
Targets identified by at least two druggability meth ods and with reported chemical inhibitors include the Bloom syndrome protein (BLM) 81 and WRN 82 helicases. WRN is of interest because of its involvement with stalled Other enzymatic targets include the dualfunction DNA endprocessing enzyme PNKP, which restores the 5′phosphate and 3′hydroxyl moieties that are required for strand break joining in both SSBR and NHEJmediated DSBR. Blocking BER and NHEJ by inhibiting PNKP is expected to result in SSL in cells that are defective in HR and could potentiate a range of genotoxic chemotherapies and radiotherapies 84, 85 . Interestingly, PNKP knockdown elicited synthetic lethality in cells lacking PTEN, a com monly mutated tumour suppressor that antagonizes PI3K signalling 7 , but the mechanism of this is not understood. Many DDR processes involve scaffold proteins that lack inherent catalytic or DNAbinding functions but that facilitate the association of functional subunits into multi protein complexes. Targeted disruption of the protein-protein interactions that the scaffold proteins mediate offers a novel approach to DDR inhibition. DDR scaffolds where this could be effective include topoi somerase 2 binding protein 1 (TOPBP1), which is essen tial for the assembly of replication initiation complexes and DNA damage checkpoint systems; XRCC1, which is essential for coordinating SSBR shortpatch repair down stream of PARP1; XRCC4 and XRCC6 (also known as KU70), which are essential for assembling the NHEJ DSBR complex; Nijmegen breakage syndrome 1 (NBS1; also known as NBN), which is essential for assembling the MRE11-RAD50-NBS1 (MRN) DSB resection complex; and PALB2, which is an essential HR component that cou ples BRCA2 to BRCA1 and RAD51 (REF. 86 ). Blocking the PALB2-BRCA2 interaction would inhibit HR and could have utility in cancers with aberrant SSBR. However, the interactions mediated by some of these scaffolds involve binding of phosphorylated motifs to basic binding sites in FHA or BRCT domains, so development of cellpenetrant competitive inhibitors of that type of protein-protein interaction may prove problematic.
Discussion
For the foreseeable future, the main route to manipula tion of an intracellular target will be via small molecules, typically acting by inhibition of a specific biochemical function of that protein. Many DDR proteins appear to be druggable in principle using this approach and offer potential new targets for cancer drug discovery. Although there are fewer straightforward enzyme cofactorbinding sites than in the pathways on which most cancer drug discovery has hitherto focused, the DDR is far from intractable, and our analysis suggests that there are many eminently druggable targets to be explored. Novelty carries increased development risks compared with triedandtested target systems, but this can be mitigated by a willingness not only to discover and design clinical leads but also to find smallmolecule chemical tools that better define and validate potential targets and that help to clarify the redundancy and interactions of the DDR target pathways. Such compounds need not be optimized for clinical use but should be specific and potent enough to demonstrate target engagement, and they should be sufficiently well tolerated to allow proofofprinciple experiments in cellular and animal models.
Beyond any issues of druggability, there is the question of how readily DDR targets can be prosecuted using a cel lular cancer drug discovery toolkit largely constructed and honed to address enzyme targets involved in post translational modification or metabolic processes. For a protein kinase or phosphatase, methyltransferase, acetyl transferase or deacetylase, the immediate pharmacologi cal effect of a putative inhibitor can be readily observed using antibodies that target the modified or unmodified state of the protein substrate of the target enzyme, or by gelshift for ubiquitylation-deubiquitylation. For a meta bolic enzyme target, the level of the direct smallmolecule product can usually be determined by mass spectrometry or by some specific secondary enzymecoupled assay.
For many DDR targets, however, especially those involved in DNA repair rather than damage signal ling, the immediate end product is normal DNA, and the effects of pharmacological inhibition of a particular pathway are observed via readouts that may be some way downstream from the target protein itself. Thus, DDR drug discovery is currently dependent on relatively gross and usually semiquantitative cellular assays such as the comet assay, which measures the levels of DSBs; the alkaline comet assay, which measures the levels of DSBs and SSBs; and immunological detection of γH2AX, a chromatin modification indicating the presence of unre paired DNA breaks in nondividing cells arising from a wide range of pathways. Clearly, as DDR targets move to the fore in cancer drug discovery, considerable effort must be invested in the development of more specific assay techniques that approach the exquisite measure ment of proximal effects that can be routinely achieved in drug discovery for cell signalling targets.
Despite these challenges, our systematic analyses of the complex DDR system, using largescale genomic, structural and pharmacological data, offer clear path ways to help focus future biological and drug discovery efforts, along with glimpses of many largely unexplored therapeutic opportunities.
